Citius Pharmaceuticals Inc News - CTXR

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination...

Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference

Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference PR Newswire CRANFORD...

Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for...

Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program

Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program PR...

Form EFFECT - Notice of Effectiveness

Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration

Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior...

Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the...

Form ARS - Annual Report to Security Holders

ironman17 1 month ago

https://www.sec.gov/Archives/edgar/data/1506251/000121390024022184/ea0201715-8k_citius.htm

👍️0

Edward 2 months ago

This was released on 2/14/2024, and the BLA was filed on 2/13/2024 with the FDA.

So if CTXR is correct CTXR should receive an answer within the next 2 weeks.

As of now, the 9:16am Pre market is looking good. Just have to wait and see if the normal trading hours follow through.

"FDA acceptance of the completed resubmission package and issuance of a Prescription Drug User Fee Act (PDUFA) date is expected within 30 days of resubmission."

https://citiuspharma.com/investors/news-media/news/release-details/2024/Citius-Pharmaceuticals-Resubmits-the-Biologics-License-Application-of-LYMPHIR-Denileukin-Diftitox-for-the-Treatment-of-Adults-with-Relapsed-or-Refractory-Cutaneous-T-Cell-Lymphoma/default.aspx

👍️0

Edward 2 months ago

Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
02/14/2024

FDA acceptance of the completed resubmission package and issuance of a Prescription Drug User Fee Act (PDUFA) date is expected within 30 days of resubmission

Link:
https://citiuspharma.com/investors/news-media/news/release-details/2024/Citius-Pharmaceuticals-Resubmits-the-Biologics-License-Application-of-LYMPHIR-Denileukin-Diftitox-for-the-Treatment-of-Adults-with-Relapsed-or-Refractory-Cutaneous-T-Cell-Lymphoma/default.aspx

👍️0

Edward 3 months ago

Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors
January 23, 2024

"This is a pivotal time for Citius as it prepares to transition from a clinical-stage company to a commercial organization"

https://citiuspharma.com/investors/news-media/news/release-details/2024/Citius-Pharmaceuticals-Announces-Nomination-of-Pharmaceutical-Executive-Robert-J.-Smith-to-its-Board-of-Directors/default.aspx

👍️0

mick 4 months ago

https://www.otcmarkets.com/stock/CTXR

👍️0

Edward 5 months ago

The shareholders will receive shares in the new company(see below).

"As previously announced, the Company is in the process of formulating a plan of distribution of a portion of the shares of Citius Oncology to its shareholders."

The wording is in the paragraph labeled(see link below) :

"CITIUS PHARMA AND TENX COMMENTS"

LINK:
citiuspharma.com/investors/...

Also, if CTXR owns 90% of the stock of the new company means they will pick up an unrealized gain if the price of the new company goes up since CTXR will carry the 90% as an investment and adjust the value to reflect the price also benefiting the stock price of CTXR and the stockholders will benefit also.

It's a win win.

👍️0

Tacostocks 5 months ago

So basically if they make a spinoff company, it hurts CTXR investors big time because they wont see the benefit.

👍️0

mick 5 months ago

https://www.otcmarkets.com/stock/CTXR

👍️0

Edward 6 months ago

Notice they said that the agreement had to be ratified by TenX but they didn't say anything about the CTXR investors having to vote on this. How could that be?

I am guessing the reason CTXR shareholders do not have to approve it is because CTXR is the only shareholder of the spin off company and the Board approved it: ( see below).

"the approval and adoption of the Merger Agreement and the transactions contemplated
thereby by the requisite vote of TenX’s shareholders (the “Parent Shareholder Approval”) and the requisite approval of Citius Pharma, as SpinCo’s sole shareholder."

👍️0

Doktornolittle 6 months ago

Wow! What just happened? I think CTXR just bought itself for $750M. Given that it had only a $107M market cap, I think that is a pretty neat trick. Actually, it bought 90% of itself for $675M. What happened to the other 10%. Is this just a 10% dilution, or is this a 10% dilution where somebody gets skewered by a factor of (750/107 )/.9 = 7.8X. Now who would that be that would get skewered (if anyone)? CTXR is held; 7.8% by Insiders, 10.7% by Institutions, so I assume about 81.5% by Retail Investors. Must be the Institutional Investors and Insiders that are getting skewered if anyone... right? That is how this works, right? SPAC's are used by non-public companies that want to go public. This time it is a public company changing it's name. New use of an SPAC? Changing it's name and probably f%$&g you in the a%##. Deep down you can feel it, can't you? Notice they said that the agreement had to be ratified by TenX but they didn't say anything about the CTXR investors having to vote on this. How could that be? Ouch! Deeper! Cut that out! You should have known that something was fishy when the 100% efficacious Mino-Lok trial that should have ended a very long time ago went silent for so long. You have to wonder if the BLA submission issues were deliberate to tank the price and give time to set this (skewering?) up. As a wealthy manager once said to me after I invented something valuable for the company and then asked for a promotion, "You (retail investors) are used to not having any money. You don't need money". They on the other hand are very very rich, so they need your money more than you need it. It's all good.

👍️0

mick 7 months ago

https://www.otcmarkets.com/stock/CTXR

👍️0

Monksdream 7 months ago

CTXR new 52 week low

👍️0

Monksdream 7 months ago

CTXR new 52 week low

👍️0

mick 8 months ago

CTXR
Citius Pharmaceuticals Inc
0.955
-0.0414 (-4.15%)
Volume: 1,010,947
Day Range: 0.9384 - 1.00
Last Trade Time: 7:48:52 PM EDT

👍️0

island man 9 months ago

Wow still alive

👍️0

mick 9 months ago

CTXR Latest News Citius Pharmaceuticals to be Added to Russell 3000® and Russell 2000® Indexes 06/26/2023 08:30:00 AM
Current Report Filing (8-k) 06/20/2023 04:06:30 PM

👍️0

mick 9 months ago

$CTXR Citius Pharmaceuticals Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids 06/20/2023 08:30:00 AM

👍️0

mick 9 months ago

$CTXR Citius Pharmaceuticals to Participate in Maxim Group's Virtual Healthcare Conference on June 21, 2023 06/13/2023 08:30:00 AM

👍️0

mick 9 months ago

$CTXR Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update 05/12/2023 04:30:00 PM

👍️0

mick 9 months ago

CTXR
Citius Pharmaceuticals Inc
1.17
-0.04 (-3.31%)
Volume: 627,282
Day Range: 1.18 - 1.24
Last Trade Time: 7:50:58 PM EDT

👍️0

jrlsss 10 months ago

Thank you. That explains it. Have my fingers crossed for a positive summer. I'm retiring next Friday, and it would be a nice safety net.
:)

👍️0

Edward 10 months ago

That was shares that were bought for the inclusion in the Russell index that was effective after the close today.

It was expected.

Today is the 4th Friday.

Every year on the fourth Friday of June, the Russell 1000, Russell 2000, Russell 3000 and other Russell indexes are reconstituted. FTSE Russell gives investors a heads up about what moves they should expect.

👍️0

jrlsss 10 months ago

What's up with the $10+ million share purchase at close?

👍️0

drkazmd65 11 months ago

Well - they have said that was their goal, and that it was 'supposed' to happen sometime during 2023. It would appear that things are moving forward.

👍️0

Edward 11 months ago

New spinoff company??

https://www.bizapedia.com/nj/citius-oncology-inc.html

👍️0

Jayzp 12 months ago

Ther Vs ctxr

Ther good news on cancer csn jump back to 52 week high

https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html

👍️0

dtgsanjose 12 months ago

best guess is that a large holder sold a chunk a couple of days ago, driving price down after a moderate run, and now a good number of folks are getting on board, seeing potential success coming a bit closer.

👍️0

drkazmd65 12 months ago

Interesting trading day here today. I can't find any new news - so I am not sure what's driving things.

👍️0

drkazmd65 1 year ago

A bit of news - Citius extends gains on advancing efforts to spin off oncology asset

https://seekingalpha.com/news/3952716-citius-stock-gains-on-spin-off-plans-for-oncology-asset

Mar. 30, 2023 9:29 AM ET
Citius Pharmaceuticals, Inc. (CTXR)
RDY
By: Dulan Lokuwithana, SA News Editor

After a 7% rise in the previous session, Citius Pharma (NASDAQ:CTXR) shares continued to gain in the pre-market Thursday after the company highlighted progress on its previously announced plans to spin off oncology candidate I/ONTAK into a standalone publicly-traded entity.

In a press release on Thursday, Citius (CTXR) said that in connection with the transaction, it has selected Maxim Group LLC as the financial advisor to its wholly-owned subsidiary, Citius Acquisition Corp.

Following the spinoff, Citius (CTXR) is expected to continue to trade on the Nasdaq under its current ticker CTXR.
I/ONTAK is a reformulation of the previously FDA-approved oncology treatment ONTAK which was available in the U.S. market from 1999 – 2014 but voluntarily withdrawn later.

Citius (CTXR) and Dr. Reddy's (RDY) have a licensing deal for I/ONTAK, which is currently under FDA review for persistent or rare blood cancer recurrent cutaneous T-cell lymphoma (CTXR), with a decision expected by Sept. 28, 2023.

Read: Seeking Alpha contributor Bret Jensen issued a Hold rating on CTXR, noting that the upcoming FDA decision on I/ONTAK is a binary event.

👍️0

KJAX 1 year ago

Who cares about E7777???

👍️0

drkazmd65 1 year ago

Fairly evenhanded article on Seeking Alpha this morning - a good read.

https://seekingalpha.com/article/4583270-citius-pharmaceuticals-stock-balanced-risk-reward-near-term-catalysts

👍️0

DTL 1 year ago

Your son left money on the table! CTXR is gaining momentum! How low did he sell for? I've been a shareholder/investor for 2 1/2 years and holding some $.87/shares, some a bit higher. I wouldn't dare trade this or sell CTXR so quickly unless desperate for money. $6 - $8/share as soon as I/Ontak and Mino-Lok hit their next milestones later this year. Get back in before the FOMO begins.

👍️ 1

Foxwoods Man 1 year ago

Maybe I am missing something but CTXR closed at $1.19 on the 24th and is at $1.32 now.

👍️0

longboarder7892 1 year ago

I just spoke with my son and he told me that CTXR if falling apart after he sold all our shares the other day. Wow this kid is getting better with his timing and taking the big profits. He will be getting a huge bonus- CTXR is down 15% today not a bad exit with a huge profit. O happy lunar new yr pp lol red is not a good look lol

longboarder7892 1 year ago

I see my son was right again on CTXR on the Jan effect play almost a double here Sold 50000 shares today but hes keeping all the call options in case it still moves higher. He has learned from the master- lol now he can pay for our vacation to Cabo

👍️0

drkazmd65 1 year ago

Looks like the presentation was received with enthusiasm - market is pretty happy with Citius today.

👍️0

longtrailer 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update
PRESS RELEASE PR Newswire
Dec. 22, 2022, 04:30 PM

https://markets.businessinsider.com/news/stocks/citius-pharmaceuticals-inc-reports-fiscal-full-year-2022-financial-results-and-provides-business-update-1031987951

👍️0

drkazmd65 1 year ago

2023 could develop into a very good year for this little pharma company.

👍️0

Edward 1 year ago

F/Y/I

Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

https://citiuspharma.com/investors/news-media/news/release-details/2022/Citius-Pharmaceuticals-Inc.-Announces-U.S.-Food-and-Drug-Administration-Acceptance-of-Biologics-License-Application-of-Denileukin-Diftitox-for-the-Treatment-of-Patients-with-Persistent-or-Recurrent-Cutaneous-T-Cell-Lymphoma/default.aspx

https://charts.stocktwits-cdn.com/production/original_492347263.png

They did say the spinoff of I/ONTAK would go into '23. They hope to have the "mechanical" aspect completed by EOY ( see link above)

👍️0

drkazmd65 1 year ago

OK - it's been a month+ since I last posted here. Anybody heard of any updates on the spin-off company idea? As I recall - the company said something about trying to do that during the 2nd half of 2022. We're rapidly running out of 2022 according to the old reliable wall calendar.

👍️0

Foxwoods Man 2 years ago

Exactly...

👍️0

drkazmd65 2 years ago

Surprisingly little positive movement after such a bit of good news today.

👍️0

Alot403 2 years ago

2 or 3. Below 10 Or -5 below. Something in that range I think.

👍️0

unityriver 2 years ago

I have a question for anyone who might have knowledge and experience in the area of spin-offs. What might be considered a typical pro rata ratio for number of shares in the new company issued to shareholders vs. number of shares held with the parent company? Thanks in advance.

👍️0

mypenneys 2 years ago

This has to BREAK $1.01 to break out on the upside. Come on guys we made it last week we can do it again.

👍️0

mypenneys 2 years ago

Looking for a short squeeze whe they spin-off the company into 2 separate companies with 2 different symbols.

👍️0

mypenneys 2 years ago

I bought at .935 cents this morning just taking a small position of 1580 shares. I also own RVVTF. Revive Therapeutics

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Citius Pharmaceuticals Inc (CTXR)

Get an advanced news scanner tailored to your needs by ADVFN

CTXR News

Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference

Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program

Form EFFECT - Notice of Effectiveness

Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration

Form S-3 - Registration statement under Securities Act of 1933

Form S-8 - Securities to be offered to employees in employee benefit plans

Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

Form 8-K - Current report

Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Form ARS - Annual Report to Security Holders

CTXR Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Citius Pharmaceuticals Inc (CTXR) News

Citius Pharmaceuticals Inc (CTXR)

Get an advanced news scanner tailored to your needs by ADVFN

CTXR News

Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference

Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program

Form EFFECT - Notice of Effectiveness

Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration

Form S-3 - Registration statement under Securities Act of 1933

Form S-8 - Securities to be offered to employees in employee benefit plans

Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

Form 8-K - Current report

Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Form ARS - Annual Report to Security Holders

CTXR Discussion

Your Recent History

Company

Business

Popular

Get The App